睿昂基因财务总监李彦年薪157万涨15%，公司股价同期跌48%营收下滑6% | 上海地区生物医药行业CFO薪酬榜

Core Insights - The report highlights the significant compensation of CFOs in the A-share market, with a total salary scale of 4.27 billion yuan and an average annual salary of 814,800 yuan for 2024 [1] - The pharmaceutical and biotechnology sector shows a higher average CFO salary of 919,700 yuan, which is 12.8% above the overall market average [1] - In Shanghai, the average CFO salary in the pharmaceutical sector reaches approximately 1,139,100 yuan, 39.8% higher than the market average, reflecting the high operational costs and talent competition in the region [1] CFO Salary Rankings - The top ten CFOs in Shanghai's pharmaceutical sector include notable figures such as Shen Bo from Shanghai Medical with a salary of 3.054 million yuan and a growth rate of 5.75% [2] - Li Yan from Ruian Gene ranks seventh with a salary of 1.573 million yuan, marking a 15.49% increase from the previous year [2][3] Company Performance - Ruian Gene reported a total revenue of 242 million yuan for 2024, a decline of 6.16% year-on-year, and a net profit of -16 million yuan, indicating a significant downturn [4] - The company's stock price fell by 48.46%, with a market capitalization of 1.03 billion yuan by the end of 2024, alongside facing compliance penalties [5] Talent Competition - The report emphasizes the strategic importance of top-tier financial executives in high-value industries, driven by the dual factors of core regional advantages and high-value industry characteristics [5]